scholarly journals Survival rate of cervical cancer from a study conducted in India

2020 ◽  
Vol 0 ◽  
pp. 1-10
Author(s):  
Ganesh Balasubramaniam ◽  
Rajshree H. Gaidhani ◽  
Arshi Khan ◽  
Sushama Saoba ◽  
Umesh Mahantshetty ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Survival Rate ◽  
Early Stage ◽  
Survival Rates ◽  
Care Facility ◽  
Mortality Rates ◽  
Survival Outcomes ◽  
Stage Of Disease ◽  
Treatment Type ◽  
Incidence And Mortality

Objectives: The incidence and mortality rates of cervical cancer in the world are 13.1/105 and 6.9/105, respectively. In India, it is estimated that there are 96,922 new cervical cancer cases and 60,078 deaths and ranked second among women cancers. The incidence and mortality rates are 14.7/105 and 9.2/105, respectively, although the incidence varies within Indian population. The majority of these cervical patients report at a late-stage of disease in health-care facility due to lack of awareness. A premier tertiary cancer hospital in Mumbai conducted the present survival-study. The aim of the study was to assess the various factors that determine the survival outcomes by age at diagnosis, role of comorbidities, stage of disease, and treatment. Material and Methods: The main source of information was patients’ medical records from which the data were abstracted, and active follow-up was undertaken. 1678 cases diagnosed between the years 2006 and 2008 at Tata Memorial Hospital are analyzed using actuarial method for obtaining survival rates and log-rank tests for comparison of survival groups. Results: The 5-year survival rate was 76.0% for those aged ≤50 years, 73.3% for non-residents, 74.4% for literates, and 81.8% for Christians and 72.5% for those with squamous cell carcinoma histology; those with no comorbidities had marginally better survival than their counter-parts. The survival rates were 83.5%, 80.6%, 66.0%, and 37.1% for Stage I, Stage II, Stage III, and Stage IV, respectively. The best survival outcomes were for those treated with only surgery (95.6%), or in combination with either radiotherapy (90.6%) or with radiotherapy and chemotherapy (85.5%). Involvement of either nodes/sites had poorer survival than those with no-involvement. In the multivariate analysis, only stage of the disease emerged as a significant prognosis factor. Conclusion: The study concluded that younger patients, early stage of disease, non-involvement of any sites/ nodes, and radiotherapy either alone or in combination with other treatment type provided better outcomes. Early detection and prevention strategies are keys to obtain better outcomes.

scholarly journals The survival rates and risk factors of implants in the early stage: a retrospective study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yong Yang ◽  
Huiting Hu ◽  
Mianyan Zeng ◽  
Hongxing Chu ◽  
Zekun Gan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Survival Rate ◽  
Dental Implants ◽  
Bone Quality ◽  
Early Stage ◽  
Survival Rates ◽  
Bone Augmentation ◽  
Early Survival ◽  
Immediate Implantation ◽  
Implant Length

Abstract Background Few large-sample studies in China have focused on the early survival of dental implants. The present study aimed to report the early survival rates of implants and determine the related influencing factors. Methods All patients receiving dental implants at our institution between 2006 and 2017 were included. The endpoint of the study was early survival rates of implants, according to gender, age, maxilla/mandible, dental position, bone augmentation, bone augmentation category, immediate implant, submerged implant category, implant diameter, implant length, implant torque, and other related factors. Initially, SPSS22.0 was used for statistical analysis. The Chi-square test was used to screen all factors, and those with p < 0.05 were further introduced into a multiple logistic regression model to illustrate the risk factors for early survival rates of implants. Results In this study, we included 1078 cases (601 males and 477 females) with 2053 implants. After implantation, 1974 implants were retained, and the early survival rate was 96.15%. Patients aged 30–60 years (OR  2.392), with Class I bone quality (OR  3.689), bone augmentation (OR  1.742), immediate implantation (OR  3.509), and implant length < 10 mm (OR  2.972), were said to possess risk factors conducive to early survival rates. Conclusions The early survival rate of implants in our cohort exceeded 96%, with risk factors including age, tooth position, bone quality, implant length, bone augmentation surgery, and immediate implantation. When the above factors coexist, implant placement should be treated carefully.

scholarly journals Efficacy of different surgical approaches on survival outcomes in patients with early-stage cervical cancer: protocol for a multicentre longitudinal study in China

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e038020
Author(s):  
Xiaopei Chao ◽  
Ming Wu ◽  
Shuiqing Ma ◽  
Xianjie Tan ◽  
Sen Zhong ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Radical Hysterectomy ◽  
Early Stage ◽  
Disease Free Survival ◽  
Learning Curves ◽  
Surgical Approaches ◽  
Survival Outcomes ◽  
Link Type ◽  
Gynecology And Obstetrics ◽  
Early Stage Cervical Cancer

IntroductionRecent studies have revealed that the oncological survival outcomes of minimally invasive radical hysterectomy (MIRH) are inferior to those of abdominal radical hysterectomy (ARH) in early-stage cervical cancer, but the potential reasons are unclear.Methods and analysisEach expert from 28 study centres participating in a previously reported randomised controlled trial (NCT03739944) will provide successive eligible records of at least 100 patients who accepted radical hysterectomy for early-stage cervical cancer between 1 January 2009 and 31 December 2015. Inclusion criteria consist of a definite pathological evaluation of stages IA1 (with positive lymphovascular space invasion), IA2 and IB1 according to the International Federation of Gynecology and Obstetrics 2009 staging system and a histological subtype of squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma. The primary endpoint is 5-year disease-free survival between the MIRH and ARH groups. The secondary endpoints include the MIRH learning curves of participating surgeons, 5-year overall survival between the MIRH and ARH groups, survival outcomes according to surgical chronology, surgical outcomes and sites of recurrence and potential risk factors that affect survival outcomes. A subgroup analysis in patients with tumour diameter less than 2 cm will follow the similar flow diagram.Ethics and disseminationThis study has been approved by the Institutional Review Board of Peking Union Medical College Hospital (registration no. JS-1711), and is also filed on record by all other 27 centres. The results will be disseminated through community events and peer-reviewed journals.Trial registration numberNCT03738969

scholarly journals National and Subnational Trends of Incidence and Mortality of Female Genital Cancers in Iran; 1990–2016

2020 ◽  
Vol 23 (7) ◽  
pp. 434-444
Author(s):  
Sahar Eftekharzadeh ◽  
Narges Ebrahimi ◽  
Mehrnoosh Samaei ◽  
Farnam Mohebi ◽  
Bahram Mohajer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Incidence Rate ◽  
Gynecological Cancer ◽  
Fold Increase ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Gynecological Cancers ◽  
Corpus Uteri ◽  
National Mortality ◽  
Incidence And Mortality

Background: The present study aims to assess the incidence and mortality rates of gynecological cancers and their changes from 1990 to 2016 at national and subnational levels in Iran. Methods: Annual estimates of incidence and mortality for gynecological cancers from 1990 to 2016 at national and subnational levels were generated as part of a larger project entitled National and Subnational Burden of Diseases, Injuries, and Risk Factors (NASBOD). After the precise processing of data extracted from the Iran Cancer Registry, annual age-standardized incidence and mortality rates were calculated for each cancer, province, year and age group during the period of the study. Results: In 2016, gynecological cancers constituted 8.0% of new cancer cases among women of all ages compared to 3.7% of new cases of cancer among women in 1990. The incidence rate of gynecological cancers has increased from 2.5 (0.9-5.6) per 100000 women in 1990 to 12.3 (9.3–15.7) per 100000 women in 2016, and the most common gynecological cancer has changed from cervical cancer in 1990 to corpus uteri cancer in 2016. Age-standardized incidence rates of ovarian, corpus uteri and vulvovaginal cancers increased from 1.3 (0.5–2.4), 1.7 (0.6–3.0), and 0.3 (0.0–0.7) in 1990 to 4.4 (3.6–5.2), 9.9 (6.8–13.4), and 0.6 (0.2–1.0) in 2016, respectively, showing a 3.3, 5.8 and 1.7-fold increase during this period. Age-standardized incidence rate of cervical cancer was 2.4 (1.7–3.3) cases per 100000 women in 2016 and did not differ significantly from the beginning of the study. An overall reduction was seen in national mortality to incidence ratios (MIR) from 2000 to 2015. Conclusion: The incidence rates of all gynecological cancers in different provinces have shown a converging trend that could indicate that attempts toward health equality have been effective. The declining trend of MIR could be interpreted as advancements in detection of cancer in its early stages and also improvements in treatments, in turn reflecting improvements in access to and quality of care.

scholarly journals The Clinicopathologic Characteristics and 3-Year Survival Rates of Epithelial Ovarian Cancer in Iran During 2011-2017

2018 ◽  
Vol 7 (4) ◽  
pp. 496-500
Author(s):  
Shahrzad Sheikh Hasani ◽  
Mitra Modares Gilani ◽  
Setareh Akhavan ◽  
Azam-Sadat Mousavi ◽  
Elham Saffarieh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Mucinous Adenocarcinoma ◽  
Survival Rates ◽  
Newly Diagnosed ◽  
Clinicopathologic Characteristics ◽  
Cross Sectional ◽  
Treatment Type

Objectives: The aim of this study was to determine the 3-year overall survival among the epithelial ovarian cancer patients based on the histology, age, and the stage of the disease in Iran during 2011-2017. Materials and Methods: This study was a cross-sectional retrospective study that was conducted on 179 newly diagnosed patients with epithelial ovarian cancer, who had referred to the gynecologic cancers clinic in a referral training hospital in Tehran during 2011-2017. The patients’ data including the demographic characteristics of the patients, the stage of the disease, and the treatment type were analyzed based on the pathologic responses. Results: Among 220 newly diagnosed patients with epithelial ovarian cancer, 179 of them were suitable for the follow-up. There were 93 death and 85 living cases among these patients and the mean age of the patients was 50.5 ± 11.3. In addition, most of the patients were in stage 3 (60.9%) and 6.7% of them were in stage 4. The most common pathology was serous adenocarcinoma (70.9%). In this study, the overall survival rate had no connection with the type of tumor histology but it was related to the stage of the disease (P=0.05). Finally, there was no mortality in stage one and among the mucinous adenocarcinoma cases. Conclusions: The survival in the epithelial ovarian cancer was related to the stage of the disease and among all the pathologies, mucinous adenocarcinoma and clear cell carcinoma had the best survival rate.

Early-Stage Cervical Cancer

2021 ◽  
pp. 139-157
Author(s):  
Maria Luisa Fais ◽  
Giorgio Candotti ◽  
Giulia Carboni ◽  
Speranza Luisa Anedda ◽  
Valerio Mais ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Early Stage ◽  
Reproductive Potential ◽  
Conservative Surgery ◽  
High Resource ◽  
Incidence And Mortality ◽  
Fertility Sparing ◽  
Early Stage Cervical Cancer ◽  
Lymph Node Assessment

Recent advances in screening and early diagnosis have decreased cervical cancer incidence and mortality rate in high-resource settings. The postponement of childbearing and the young age of women at diagnosis produced new challenges in the management of this disease. In recent years, attention has been directed to assessing more conservative procedures that can reduce treatment-related morbidity, without compromising oncologic safety and reproductive potential. Fertility sparing surgery (FSS) procedures, including cervical conization, simple or radical trachelectomy with pelvic nodes dissection or sentinel lymph node assessment, and neoadjuvant chemotherapy followed by conization, have shown encouraging results. In this chapter, the authors discuss the role of conservative surgery in the management of early-stage cervical cancer focusing on obstetrical and oncological outcomes.

scholarly journals Cancer in Africa: Is It a Genetic or Environmental Health Problem?

2020 ◽  
Vol 10 ◽  
Author(s):  
Abeer A. Bahnassy ◽  
Mona S. Abdellateif ◽  
Abdel-Rahman N. Zekri
Keyword(s):  
Health Problem ◽  
African Ancestry ◽  
Survival Rates ◽  
Mortality Rates ◽  
Sociocultural Factors ◽  
Major Health Problem ◽  
Major Health ◽  
Incidence And Mortality ◽  
Environmental Health Problem ◽  
African Patients

Patients of African ancestry have the poorest outcome and the shortest survival rates from cancer globally. This could be attributed to many variables including racial, biological, socioeconomic and sociocultural factors (either single, multiple or combined), which may be responsible for this major health problem. We sought to assess the most common types of cancer that endanger the health of the African people, and tried to investigate the real differences between African and other Non-African patients regarding incidence, prevalence and mortality rates of different cancers. Therefore, identifying the underlying aetiological causes responsible for the increased incidence and mortality rates of African patients will allow for changing the current plans, to make optimized modalities for proper screening, diagnosis and treatment for those African patients, in order to improve their survival and outcomes.

Solitary Plasmacytoma Incidence, Mortality, and Survival Trends in the United States

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5629-5629
Author(s):  
Anirudh Bikmal ◽  
Lakshmi Radhakrishnan ◽  
Ajay K. Nooka
Keyword(s):  
Regression Analysis ◽  
Black Males ◽  
Survival Rates ◽  
The United States ◽  
Mortality Rates ◽  
Incidence Rates ◽  
Study Cohort ◽  
Solitary Plasmacytoma ◽  
Incidence And Mortality ◽  
Adjusted Incidence

Abstract Background: The trends of incidence of solitary bone plasmacytoma (SBP) varied over time due to the changing definitions and the absence of clarity of the criteria. Prior studies have attempted to identify factors such as older age, gender, race as prognostic factors that influence survival of patients with SBP, but with changing paradigm of myeloma treatments, there is limited literature regarding the incidence, mortality and survival trends of SBP. Methods: We used the SEER registry from 1973-2009 to evaluate the incidence, mortality and survival trends in patients with SBP. The results were reported as crude incidence, mortality and survival rates. Two-sample t-tests, ANOVA as well regression analysis were used to examine correlation. Statistics were computed using the National Cancer Institute SEER*Stat software, version 8.2.0. and SAS software, version 9.4 (SAS Institute Inc, Cary, NC). Using the ICD-O-3 and morphologic codes of 9731/3 to identify cases, the final study cohort consisted of 2,734 cases. Trends were evaluated by the eras of diagnosis: 1973-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2000, 2001-2005, and 2006-2009. Age-adjusted incidence rates (IR), standard mortality rates (SMR), survival rate (SR) were expressed as new cases per 100,000 person-years, and age-adjusted to the 2000 US standard population. Results: The median age of diagnosis of SBP among blacks is 61 years (range, 21-91) compared to others: 60 years (range, 28-88) and whites: 66 years (20-97). The age adjusted incidence rates for black males is: 0.3 (95%CI 0.2, 0.3) followed by black females 0.2 (95%CI 0.1, 0.2) white males 0.2 (95%CI 0.2, 0.2) white females 0.1 (95%CI 0.1, 0.1). The trends in incidence and mortality rates are illustrated in table 1 with highest IR noted for black males during the era 2006-2009. The 5-year survival rates for both males (figure 1) and females (figure 2) seem to be trending down over the eras examined. Regression analysis suggests males and other race have increased odds of survival (HR = 0.829, p=0.0078; HR = 0.54 and p=0.0038, respectively). Conclusions: Similar to myeloma, black patients tend to be diagnosed with SBP younger and have increased incidence. The incidence rates seem to be increasing, highest among blacks males, more likely from increased awareness and diagnosis. The mortality and survival patterns are comparable to whites. Interestingly, while the 5-year survival for myeloma among all racial groups is improving this analysis shows a decreasing trend for SBP. This observation is more likely from including myeloma patients under the diagnosis of SBP over the period of study. Recently, the International Myeloma Working Group (IMWG) clarified the definition of SBP which will help in accurate diagnosis and ultimately can help in accurate representation of the survival trends. Table 1. Incidence and Mortality Rates across Study Eras (SEER-9), 1973-2009 Years White (IR) White (MR) Black (IR) Black (MR) Other (IR) Other (MR) Male 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1986-1990 0.1 (0.1, 0.2) 0.1 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 0.3 (0.1, 0.5) 0 (0, 0.2) 1991-1995 0.2 (0.1, 0.2) 0.1 (0.1, 0.2) 0.2 (0.1, 0.4) 0 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 1996-2000 0.2 (0.2, 0.3) 0.1 (0.1, 0.1) 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 0.2 (0, 0.4) 2001-2005 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.5 (0.3, 0.7) 0.3 (0.1, 0.6) 0.2 (0, 0.2) 0 (0, 0.2) 2006-2009 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.7 (0.4, 1) 0.3 (0.1, 0.5) 0.1 (0, 0.2) 0.1 (0, 0.2) Female 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1986-1990 0.1 (0, 0.1) 0 (0, 0.1) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.2) 1991-1995 0.1 (0.1, 0.1) 0 (0, 0.1) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.1) 1996-2000 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0, 0.2) 0.1 (0, 0.2) 0.1 (0.2) 0 (0, 0.1) 2001-2005 0.2 (0.2, 0.2) 0.1 (0.1, 0.2) 0.3 (0.2, 0.4) 0.1 (0, 0.2) 0.1 (0, 0.2) 0 (0, 0.1) 2006-2009 0.2 (0.2, 0.3) 0.1 (0.1, 0.2) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Disclosures Nooka: Spectrum Pharmaceuticals: Consultancy; Onyx Pharmaceuticals: Consultancy.

Sign in / Sign up

Export Citation Format

Share Document